Adjuvanted nanoliposomes displaying six hemagglutinins and neuraminidases as an influenza virus vaccine.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 38401547.
- Also identified by DOI 10.1016/j.xcrm.2024.101433 and PMC identifier 10982964.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Inclusion of defined quantities of the two major surface proteins of influenza virus, hemagglutinin (HA) and neuraminidase (NA), could benefit seasonal influenza vaccines. Recombinant HA and NA multimeric proteins derived from three influenza serotypes, H1N1, H3N2, and type B, are surface displayed on nanoliposomes co-loaded with immunostimulatory adjuvants, generating "hexaplex" particles that are used to immunize mice. Protective immune responses to hexaplex liposomes involve functional antibody elicitation against each included antigen, comparable to vaccination with monovalent antigen particles. When compared to contemporary recombinant or adjuvanted influenza virus vaccines, hexaplex liposomes perform favorably in many areas, including antibody production, T cell activation, protection from lethal virus challenge, and protection following passive sera transfer. Based on these results, hexaplex liposomes warrant further investigation as an adjuvanted recombinant influenza vaccine formulation.
Medical subject headings
- Influenza Vaccines
- Orthomyxoviridae Infections
- Influenza A Virus, H1N1 Subtype
- Influenza, Human